CYTEK BIOSCIENCES, INC. Increase (Decrease) in Accrued Liabilities
CYTEK BIOSCIENCES, INC. (CTKB) reported Increase (Decrease) in Accrued Liabilities of $227.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $4.12M, a 47.51% increase year-over-year.
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$3.89M.
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $4.71M, a 60.28% increase year-over-year.
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$1.41M, a 125.01% decline year-over-year.
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $3.97M.
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$817.00K, a 212.07% decline from fiscal 2023.
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $729.00K, a 90.24% decline from fiscal 2022.
- CYTEK BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $7.47M, a 31.95% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $227.00K 10-Q · filed 2026-08-05 | $4.94M derived: sum of 3 quarters · filed 2026-08-05 | $3.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.89M 10-Q · filed 2026-05-07 | $819.00K derived: sum of 2 quarters · filed 2026-05-07 | -$590.00K derived: sum of 3 quarters · filed 2026-05-07 | $2.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.30M derived: sum of 2 quarters · filed 2026-02-26 | $6.09M derived: sum of 3 quarters · filed 2026-08-05 | $3.97M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.38M derived: sum of 2 quarters · filed 2026-08-05 | -$739.00K 10-Q · filed 2025-11-05 | $2.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $670.00K 10-Q · filed 2026-08-05 | $3.61M derived: sum of 3 quarters · filed 2026-08-05 | $9.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.12M 10-Q · filed 2026-05-07 | $817.00K derived: sum of 2 quarters · filed 2026-05-07 | $6.45M derived: sum of 3 quarters · filed 2026-05-07 | $1.66M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.57M derived: sum of 2 quarters · filed 2026-02-26 | $3.78M derived: sum of 3 quarters · filed 2026-02-26 | -$817.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $844.00K derived: sum of 2 quarters · filed 2025-11-05 | -$3.75M 10-Q · filed 2025-11-05 | -$3.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$4.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$9.39M 10-Q · filed 2025-08-06 | -$9.27M derived: sum of 3 quarters · filed 2026-02-26 | -$8.94M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$4.60M 10-Q · filed 2025-05-08 | -$4.48M derived: sum of 2 quarters · filed 2026-02-26 | -$4.14M derived: sum of 3 quarters · filed 2026-02-26 | -$5.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $454.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.03M derived: sum of 3 quarters · filed 2026-02-26 | $729.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $335.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.15M derived: sum of 2 quarters · filed 2024-11-07 | $610.00K 10-Q · filed 2024-11-07 | $5.25M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $275.00K 10-Q · filed 2024-08-06 | $4.92M derived: sum of 3 quarters · filed 2025-02-28 | $4.96M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.76M 10-Q · filed 2024-05-08 | $6.41M derived: sum of 2 quarters · filed 2025-02-28 | $6.45M derived: sum of 3 quarters · filed 2025-02-28 | $8.68M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $4.69M derived: sum of 2 quarters · filed 2025-02-28 | $6.92M derived: sum of 3 quarters · filed 2025-02-28 | $7.47M 10-K · filed 2025-02-28 |
| 2022-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.27M derived: sum of 2 quarters · filed 2023-11-14 | $2.83M 10-Q · filed 2023-11-14 | $11.71M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.78M 10-Q · filed 2023-08-08 | $11.66M derived: sum of 3 quarters · filed 2024-03-13 | $13.26M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $555.00K 10-Q · filed 2023-05-09 | $9.43M derived: sum of 2 quarters · filed 2024-03-13 | $11.03M derived: sum of 3 quarters · filed 2024-03-13 | $11.40M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $10.47M derived: sum of 2 quarters · filed 2024-03-13 | $10.84M derived: sum of 3 quarters · filed 2024-03-13 | $10.98M 10-K · filed 2024-03-13 |
| 2021-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.96M derived: sum of 2 quarters · filed 2022-11-09 | $2.10M 10-Q · filed 2022-11-09 | $3.61M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $370.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $505.00K 10-Q · filed 2022-08-10 | $2.01M derived: sum of 3 quarters · filed 2023-03-01 | $3.96M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $135.00K 10-Q · filed 2022-05-12 | $1.64M derived: sum of 2 quarters · filed 2023-03-01 | $3.59M derived: sum of 3 quarters · filed 2023-03-01 | |
| 2020-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.46M derived: sum of 2 quarters · filed 2023-03-01 | $3.27M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.76M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$190.00K 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |